Amylyx Pharmaceuticals In...

NASDAQ: AMLX · Real-Time Price · USD
8.01
-0.40 (-4.76%)
At close: Aug 15, 2025, 3:59 PM
8.00
-0.12%
After-hours: Aug 15, 2025, 04:10 PM EDT

Amylyx Pharmaceuticals Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
77.39M 170.2M 62.53M 50.19M
Short-Term Investments
99.11M 201.16M 284.42M 45.93M
Long-Term Investments
n/a n/a 719K 189K
Other Long-Term Assets
1.47M 46.38M 466K 3.44M
Receivables
447K 40.05M 15.31M n/a
Inventory
n/a 38.32M 9.77M n/a
Other Current Assets
12.48M 14.93M 10.11M 3.44M
Total Current Assets
189.43M 464.67M 382.13M 101.51M
Property-Plant & Equipment
2.73M 6.41M 8.13M 474K
Goodwill & Intangibles
n/a n/a n/a n/a
Total Long-Term Assets
4.2M 52.79M 9.32M 4.1M
Total Assets
193.63M 517.45M 391.45M 105.61M
Account Payables
2.94M 22.06M 6.26M 4.37M
Deferred Revenue
n/a n/a n/a n/a
Short-Term Debt
1.52M n/a 2.04M n/a
Other Current Liabilities
23.95M 40.93M 21.04M n/a
Total Current Liabilities
28.41M 82.04M 46.61M 17.4M
Long-Term Debt
n/a n/a n/a n/a
Other Long-Term Liabilities
n/a n/a n/a 35K
Total Long-Term Liabilities
463K 1.98M 4.24M 239.39M
Total Liabilities
28.87M 84.02M 50.85M 256.78M
Total Debt
1.98M 4.24M 6.28M n/a
Common Stock
7K 7K 7K 1K
Retained Earnings
-606.69M -304.95M -354.22M -155.84M
Comprehensive Income
-92K 197K -86K 9K
Shareholders Equity
164.76M 433.43M 340.61M -151.17M
Total Investments
99.11M 201.16M 284.42M 45.93M